Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | DDR1 | Q08345 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.43 |
| ▸ | VNN1 | O95497 | 2/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.42 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | CSF1R | P07333 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1004777 | 0.89 | CES2 (0.59) | CES2GAAMAPTHDAC3HDAC6 | |
| SCHEMBL25795128 | 0.84 | AKT1 (0.50) | CES2GAAMAPTHDAC3HDAC6 | |
| SCHEMBL13753158 | 0.83 | DDR1 (0.47) | CES2DDR1GAAHDAC3HDAC6 | |
| SCHEMBL114726 | 0.82 | CES2 (0.54) | CES2GAAHDAC6HDAC1HDAC2 | |
| SCHEMBL2456614 | 0.82 | GAA (0.50) | CES2GAAMAPTHDAC3HDAC6 | |
| SCHEMBL29889675 | 0.82 | GAA (0.50) | CES2GAAMAPTHDAC3HDAC6 | |
| SCHEMBL25757925 | 0.82 | CES2 (0.47) | CES2DDR1GAAHDAC3HDAC6 | |
| SCHEMBL13753001 | 0.81 | DDR1 (0.55) | CES2DDR1GAAVNN1NOTUM | |
| SCHEMBL13753151 | 0.81 | NPSR1 (0.63) | CES2DDR1GAAHDAC8NOTUM | |
| SCHEMBL23977170 | 0.81 | ADCY8 (0.51) | HDAC6ADCY8ADCY1KDM4EHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230353959-A1 | PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2023-11-02 | — | — | US | disclosed |
| WO-2023098880-A1 | FUSED RING DERIVATIVE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 上海翰森生物医药科技有限公司 | 2023-06-08 | — | — | WO | disclosed |
| WO-2023081759-A1 | BIFUNCTIONAL PI3K-ALPHA INHIBITORS AND USES THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023288242-A1 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2021222556-A1 | PI3K-α INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20130177529-A1 | Pyrazole Compounds | VIVOQUEST, INC. | 2013-07-11 | — | — | US | disclosed |
| US-8329703-B2 | Pyrazole compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-12-11 | — | — | US | disclosed |
| US-8329703-B2 | Pyrazole compounds | XTL BIOPHARMACEUTICALS LTD. (IL) | 2012-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130177529-A1 | Pyrazole Compounds | MAVS, EIF2AK2, ZC3HAV1 | CES2 865/4885DDR1 4604/4885GAA 454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.